ACRO urges modernization of the R&D Tax Credit

Wednesday, November 22, 2017

As the Senate begins debate on a tax reform bill, the clinical research industry hopes that attention will be given to a small but substantive issue—updating a tax code provision that has had strong bipartisan support for more than 30 years.

[Read More]

ACRO testifies about clinical trials in New Jersey

Tuesday, October 24, 2017

ACRO Executive Director Doug Peddicord, Ph.D., testified at a public hearing of the New Jersey Division of Consumer Affairs about a regulation that, if adopted, would have a devastating impact on the availability of clinical trials for patients in New Jersey and cripple the ability of New Jersey physicians to conduct industry-sponsored clinical trial research on investigational therapies.

[Read More]

Study: Americans would participate in clinical trials if doctor recommended

Wednesday, September 6, 2017

The Association of Clinical Research Organizations (ACRO) applauds Research!America for a recently released survey on the public’s perception of clinical trials. The study, funded in part by ACRO and conducted by Zogby Analytics, surveyed 1,000 adults nationwide in July 2017 and found that an overwhelming majority (86%) believe that doctors should discuss clinical trials with patients as part of standard care.

[Read More]

Survey: Discussions about clinical trials should be part of standard of care

Tuesday, July 25, 2017

An overwhelming majority of Americans (86%) agree that healthcare professionals should discuss clinical trials with patients diagnosed with a disease as part of their standard of care, according to a new national public opinion survey commissioned by Research!America. And three-quarters of respondents (75%) agree that taking part in clinical trials is as valuable to our health care system as giving blood. But Americans are split on whether it’s important for everyone to take part in a clinical trial if they are asked—44% agree while 45% disagree and 12% are not sure. A higher percentage (74%) said they would participate if they are asked by someone they trust.

[Read More]

Innovation Initiative to modernize the FDA

Monday, July 17, 2017

New FDA Commissioner Scott Gottlieb intends to release a far-reaching plan aimed at modernizing regulatory processes and speeding approvals for new drugs and devices, which could allow greater patient access to new medicines through unprecedented scientific and technological advancements.

[Read More]

Three Questions: Norman Goldfarb, MAGI

Monday, May 15, 2017

CWWeekly presents this biweekly feature as a spotlight on issues that executives in clinical research face. This week, writer Suz Redfearn spoke with Norman Goldfarb, chairman of Model Agreements & Guidelines International (MAGI), an organization that has spent a decade promoting the standardization of clinical trial agreements (CTAs) and contract templates that both sites and CROs or sponsors can use to speed study startup. Goldfarb is also editor of The Journal of Clinical Research Best Practices, and managing director of First Clinical Research. In April, the Association of Clinical Research Professionals gave Goldfarb their award for innovation for the MAGI CTA initiative.

[Read More]

Domestic Research Enhancement Act of 2017 endorsed by many

Tuesday, April 11, 2017

The Domestic Research Enhancement Act of 2017 (H.R. 1234), which modernizes the R&D tax credit to recognize the essential role contract research now plays in the development of new pharmaceuticals, biologics and medical devices, has been introduced by Rep. Pat Meehan (R-PA) and co-sponsors Rep. George Holding (R-NC) and G.K. Butterfield (D-NC).

[Read More]